PBIO - Pressure BioSciences, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
3.0700
+0.1200 (+4.07%)
At close: 3:50PM EDT
Stock chart is not supported by your current browser
Previous Close2.9500
Open3.0900
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range3.0000 - 3.3000
52 Week Range1.2500 - 4.1000
Volume7,748
Avg. Volume11,778
Market Cap5.95M
Beta (3Y Monthly)0.84
PE Ratio (TTM)N/A
EPS (TTM)-9.0880
Earnings DateNov 12, 2019 - Nov 22, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.57
Trade prices are not sourced from all markets
  • GlobeNewswire

    Pressure BioSciences Prepares for Growth, Adding Daniel J. Shea as Chief Financial Officer 

    Shea’s 30-Year Diverse Experience in Acquisitions, Capital Markets, SEC Reporting, and Leading Financial Organizations Bolsters PBI’s Strong Senior Management Team South.

  • GlobeNewswire

    Pressure BioSciences’ PCT Platform Identified as Pivotal for Cancer Biomarker Discovery and for Potential Clinical Diagnostics

    SOUTH EASTON, MA, Sept. 10, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Pressure BioSciences, Inc. (PBIO) (“PBI” and the “Company”) is a leader in the development and sale of innovative, broadly enabling, pressure-based instruments and related consumables for the worldwide life sciences and other industries. The Company announced today the publication of two scientific journal articles, led by independent teams of  scientists in China and Australia, reporting excellent results with PBI’s Pressure Cycling Technology (“PCT”) platform in processing preserved formalin-fixed paraffin-embedded (“FFPE”) and fresh frozen biopsy tissue samples for discovery and elucidation of cancer biomarkers and potentially for use in clinical diagnostics based upon these markers.  The Chinese team from Westlake University (Hangzhou, China) purchased their first two PCT platforms in 2017 and subsequently purchased four additional PCT systems.  The Australian Proteome of Human Cancer (“ProCan”) team bought their first PCT system in 2016 and have subsequently added five more PCT platforms.

  • Newsfile

    InvestmentPitch Media Video Discusses Pressure BioSciences' Two Purchase Orders for its Revolutionary BaroShear(tm) K45 Processing System for CBD Nanoemulsion - Video Available on Investmentpitch.com

    Vancouver, British Columbia--(Newsfile Corp. - August 27, 2019) - Pressure BioSciences, Inc. (OTCQB: PBIO) announced two additional purchase orders for its revolutionary BaroShear™ K45 processing system. Based on the company's proprietary Ultra Shear Technology™ (UST™) platform, the BaroShear K45 is a unique and powerful nanoemulsification system designed to resolve one of the most critical problems facing CBD manufacturers today: the extremely poor solubility of CBD Oil in water. Cannot view this video? ...

  • GlobeNewswire

    Pressure BioSciences Announces Two More Purchase Orders for its Revolutionary BaroShear K45 Processing System for Manufacturing Water-Soluble CBD

    SOUTH EASTON, MA, Aug. 22, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Pressure BioSciences, Inc. (PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sciences industry, today announced it has received two additional purchase orders for its revolutionary BaroShear™ K45 processing system. This novel processing system is based on the Company’s proprietary Ultra Shear Technology™ (UST™) platform. The BaroShear K45 is a unique and powerful nanoemulsification system designed to resolve one of the most critical problems facing the CBD industry today: the extremely poor solubility of CBD Oil in water.

  • ACCESSWIRE

    Pressure BioSciences, Inc. Reports Second Quarter 2019 Financial Results and Provides Business Update

    Record Consumables Sales, Strong Growth in BaroFold & UST Services, and Launch of Revolutionary CBD Processing System Highlight the 2019 Second Quarter; Company Believes Total Revenue Will More than Double ...

  • Newsfile

    Stock Day Media Shares Discovery of Revolutionary Technology that Can Make High Quality, Highly Stable, Water-Soluble Nanoemulsions of CBD Oil with Pressure and Shear (Physics), Not Chemicals

    Phoenix, Arizona--(Newsfile Corp. - August 14, 2019) - Stock Day Media prides itself in discovering companies with highly talented staff, revolutionary technologies, and the experience to combine these two key assets to change an industry. We have been watching an intriguing company for several years now, and with the news they recently released, we believe they are truly a company that has the talent, technology, experience, patent protection, and know-how to change ...

  • ACCESSWIRE

    Pressure BioSciences, Inc. to Discuss Second Quarter 2019 Financial Results and Provide Business Update

    Conference Call Scheduled for Thursday, August 15 th at 4:30pm ET SOUTH EASTON, MA / ACCESSWIRE / August 13, 2019 / Pressure BioSciences, Inc. (OTCQB:PBIO) (“PBI” and the “Company”) today announced that ...

  • ACCESSWIRE

    Pressure BioSciences Announces First Close and Customer for its Revolutionary Water-Soluble CBD Manufacturing System, the BaroShear K45

    SOUTH EASTON, MA / ACCESSWIRE / July 25, 2019 / Pressure BioSciences, Inc. (PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sciences industry, today announced the initial sale of its revolutionary BaroShear™ K45 processing system. This novel instrument system is based on the Company’s proprietary Ultra Shear Technology™ (UST™) platform.

  • ACCESSWIRE

    Pressure BioSciences Announces Second Major Contract Utilizing its BaroFold Protein Refolding and Disaggregation Biopharma Services

    SOUTH EASTON, MA / ACCESSWIRE / July 24, 2019 / Pressure BioSciences, Inc. (PBIO) (“PBI” and the “Company”), a leader in the development and sale of broadly enabling, high pressure-based instruments, platform technologies and related consumables for the worldwide life sciences industry, today announced it has signed a contract services agreement with a world-renown, multi-billion dollar biotherapeutics company to enhance the process manufacturing of one of their candidate protein drugs. The manufacturing of therapeutic proteins can be a complex and challenging process.

  • ACCESSWIRE

    Pressure BioSciences' PCT Platform Highlighted at International Conference in China

    SOUTH EASTON, MA / ACCESSWIRE / July 18, 2019 / Pressure BioSciences, Inc. (PBIO) (“PBI” and the “Company”), a leader in the development and sale of innovative, broadly enabling, pressure-based instruments and related consumables for the worldwide life sciences and other industries, today announced that its flagship Barocycler 2320EXTREME instrument was prominently featured at a three-day, internationally-attended scientific conference held at the elite Westlake University (“Westlake”) in Hangzhou, China. One of the primary conference organizers was Professor Tiannan Guo, MD., PhD, a well-known protein research scientist. In 2017, Professor Guo’s Westlake laboratory was named a PBI Center of Excellence.

  • ACCESSWIRE

    Pressure BioSciences Enters CBD Market with Launch of Novel Instrument System to Revolutionize Manufacturing of High Quality, Water-Soluble CBD

    SOUTH EASTON, MA / ACCESSWIRE / June 27, 2019 / Pressure BioSciences, Inc. (PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sciences industry, today announced the launch of its BaroShear™ K45 system based on the Company's proprietary Ultra Shear Technology™ (UST™) platform. The BaroShear K45 system is a unique and powerful next generation nanoemulsification system designed to fix one of the most critical problems facing CBD manufacturers today: the extremely poor water solubility of CBD oil. Because of these solubility issues, many CBD products on the market today contain an inefficient over-abundance of CBD and/or undesirable chemicals to try and improve its solubility in water.

  • ACCESSWIRE

    Pressure BioSciences Announces Achievement of First Major Milestone in Development of Potential Breakthrough Processing Method for Higher Quality and Safer Food and Beverages

    Proprietary, Custom Built UST-Based Instrument Delivered to Collaborators at The Ohio State University; OSU Scientists to Study Pressure and Shear Effects on Pathogen Inactivation, Stability, and Quality ...

  • ACCESSWIRE

    Pressure BioSciences' Ultra High Pressure HUB Platform Highly Effective in Studies to Develop Improved Methods for Food Safety

    HUB Platform Plays Critical Role in Innovative Research Studies Designed to Increase Understanding of and Develop Methods for the Prevention of Serious Food-Borne Diseases Caused by E. coli and Listeria ...

  • ACCESSWIRE

    Pressure BioSciences' PCT Platform Prominently Featured in Record Number of Presentations at Major International Science Conference

    SOUTH EASTON, MA / ACCESSWIRE / June 12, 2019 / Pressure BioSciences, Inc. (PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-base instruments, consumables, and platform technology solutions to the worldwide life sciences industry, today announced that the Company's patented pressure cycling technology ("PCT") platform was prominently featured in 15 independent presentations at the annual conference of the American Society for Mass Spectrometry ("ASMS"), held from June 1-6, 2019 in Atlanta, GA. The presentations spanned wide ranging applications for PBI's unique PCT platform in scientific studies, particularly their essential use in advancing knowledge and understanding in such areas as cancer research, protein function, molecular biology, and biomarker discovery.

  • ACCESSWIRE

    Pressure BioSciences, Inc. Reports First Quarter 2019 Financial Results and Provides Business Update

    Q1 Revenue from Newly Created BioPharma and UST Contract Services Significantly Exceeds Services Revenue for All Quarters of 2018 Combined Investor Conference Call Scheduled for Thursday, May 16, 2019 ...

  • ACCESSWIRE

    Pressure BioSciences, Inc. to Discuss First Quarter 2019 Financial Results and Provide Business Update

    Conference Call Scheduled for Thursday, May 16 th at 4:30pm ET SOUTH EASTON, MA / ACCESSWIRE / May 15, 2019 / Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company") today ...

  • ACCESSWIRE

    Pressure BioSciences Announces CEO Succession Plan

    SOUTH EASTON, MA / ACCESSWIRE / May 1, 2019 / Pressure BioSciences, Inc. (PBIO) ("PBI" and the "Company"), a leader in the development and sale of innovative, broadly enabling, pressure-based instruments and related consumables for the worldwide life sciences industry, today announced that Mr. Richard T. Schumacher, the Founder of the Company, notified the Company's Board of Directors on April 25, 2019 that he plans to step down as President and CEO effective September 9, 2019. Mr. Schumacher has been working with the Company's Board of Directors on leadership succession planning for many months, including the selection of Bradford A. Young, PhD, MBA, as SVP & Chief Commercial Officer ("CCO") for the Company in November 2018.

  • ACCESSWIRE

    Pressure BioSciences, Inc. Reports Record Fourth Quarter and Fiscal Year 2018 Financial Results and Provides Business Update

    Q4 2018 Total Revenue Increases 37% over Q4 2017, Setting New Record Quarterly High; FY 2018 Total Revenue Increases 10% over FY 2017, Setting New Record Annual High; Initial Revenue Reported from New ...

  • ACCESSWIRE

    Pressure BioSciences, Inc. to Discuss Fourth Quarter and Fiscal Year 2018 Financial Results and Provide Business Update

    Conference Call Scheduled for Thursday, April 25 th at 4:30pm ET SOUTH EASTON, MA / ACCESSWIRE / April 24, 2019 / Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company") ...

  • CNW Group

    Widespread Clinical Studies Can Reinvigorate the Legalization Movement for Cannabis

    The Tufts Center for the Study of Drug Development estimated that in 2017, it cost pharmaceutical companies approximately USD 2.7 Billion to bring medicine from invention stages to shelves. Now, the growing concern over the mental and physical health damage caused by traditional medicines have prompted medical institutes to reevaluate, which has, in turn, brought forth medical cannabis into the spotlight. Small-scale research and clinical trials have concluded that medical cannabis can effectively treat medical conditions that common medications such as opioids also treat.

  • CNW Group

    Some New Patients Choose CBD in Lieu of Opioids to Treat Persistent Ailments

    NEW YORK, April 9, 2019 /CNW/ -- Nearly 20% of U.S. adults suffer from chronic pain, while 8% are diagnosed with high-impact chronic pain, according to the National Institute of Health. Researchers from the Centers for Disease Control and Prevention (CDC), National Institutes of Health, Stanford Division of Pain Medicine, Kaiser Permanente, and Yale University concluded that chronic pain problems actually limited certain daily tasks in patients' lives. Traditionally, most patients who suffer from chronic pain are prescribed opioids like hydrocodone and oxycodone in order to suppress the pain.

  • ACCESSWIRE

    Uptick Newswire Hosts Dr. Bradford A. Young of Pressure BioSciences, Inc., on The Stock Day Podcast to Discuss the Commercialization of PBI's Proprietary UST and BaroFold Technology Platforms

    PHOENIX, AZ / ACCESSWIRE / April 8, 2019 / Uptick Newswire recently welcomed Dr. Bradford A. Young, Senior Vice President and Chief Commercial Officer of Pressure BioSciences, Inc. (PBIO) ("PBI" or "the Company") to The Stock Day Podcast. The interview was hosted by Mr. Everett Jolly. To begin the interview, Mr. Jolly asked Dr. Young what makes the Company's Ultra Shear Technology (UST) platform one of the most effective methods known when it comes to mixing CBD oil and water.

  • CNW Group

    CBD and Cannabis Markets Continues to Grow Despite Regulations

    Specifically, the recent bout of legalization efforts has caused consumers to flock to brick-and-mortar or even e-commerce stores to purchase cannabis-based products. For instance, Canada recently legalized cannabis in late 2018, however, the country is struggling to keep up with consumer demand. Despite these regulatory concerns though, the cannabis industry is still positioned to become a disruptive and global marketplace.

  • CNW Group

    Research and Regulatory Agencies add Credibility to the Rapidly Growing CBD Market

    NEW YORK, April 3, 2019 /CNW/ -- The cannabis marketplace has become one of the fastest growing global industries, as the rapid expansion of the cannabis market is largely due to the ongoing legalization efforts in many countries. The medical cannabis sector currently accounts for a majority of the market value due to the legal hindrances imposed on recreational cannabis. Medical cannabis, on the other hand, is generally more accepted among virtually every country and now, many governments are adopting medical cannabis legislation in order to use cannabis as an alternative to traditional medication.

  • ACCESSWIRE

    CBD-Infused Beverages Achieve Quality and Clarity Breakthrough Utilizing Pressure BioSciences' Ultra Shear Technology Platform

    New Video Demonstrates Revolution in Soft Drinks, Sports Drinks, and Beer with Vanishing Water-Soluble CBD Oil for Enhanced Quality and Absorption SOUTH EASTON, MA / ACCESSWIRE / April 2, 2019 / Pressure ...